Behavioral Diagnostics

Executive Summary

Behavioral Diagnostics is a private, early-stage diagnostics company headquartered in Iowa City, Iowa, focused on developing methylation-based tests for early detection of cancer and substance addiction. Founded in 2012, the company aims to make early detection accessible to everyone, leveraging epigenetic biomarkers to identify disease at its earliest stages. Their platform technology analyzes DNA methylation patterns in blood or other samples to detect cancer and addiction-related changes before symptoms arise. While still in development, the approach has potential to significantly improve outcomes through earlier intervention and could address major public health challenges in oncology and addiction medicine. The company's progress and regulatory pathway remain largely opaque given limited public disclosures, but its focus on non-invasive, epigenetics-based screening aligns with industry trends toward precision diagnostics.

Upcoming Catalysts (preview)

• Q4 2026Initiation of a pivotal clinical trial for a cancer detection test30% success
• Q3 2026Strategic partnership or licensing deal with a larger diagnostics company40% success
• Q2 2026Publication of key validation data in a peer-reviewed journal50% success